Category Leaders Are Built, Not Born
We partner with early-stage startups to build breakout brands from day one—using strategic and creative services that transform early momentum into lasting market leadership. The best brands win. We ensure you’re one of them.
Our Model
We invest capital and services
We are a rare breed in the venture world, bringing typically inaccessible world-class strategic and creative execution to early-stage companies in a capital-efficient manner.
We fill a unique role on cap tables
We partner with lead investors by bringing complimentary, non-duplicative expertise. We bring a strategic and brand-centric perspective to deals and aim to be a secret weapon for the best VCs in the world.
We partner deeply with founders
We have a deep bench of talent who have experience and relationships with the most senior leaders at key customers and strategic partners. We bring operational and execution depth to teams.
We have spent the last 18+ years working with and building the best and strongest brands in the world.
Demos Invests in Minutia to Transform the Future of Type 1 Diabetes Treatment
We're thrilled to announce our investment in Minutia, an innovative biotech company developing a groundbreaking functional cure for Type 1 Diabetes (T1D). Minutia combines cutting-edge stem cell biology with advanced nanosensor technology to fundamentally reshape diabetes therapy.
Minutia’s pioneering approach integrates stem cell-derived insulin-producing cells with proprietary gold nanoparticle sensors. This unique combination not only closely replicates the body’s natural insulin production but also includes real-time monitoring capabilities and a built-in thermal "kill switch" for enhanced safety—representing a transformative leap forward in cell-based therapies.
Unlike traditional therapies that require implantation into higher-risk organs like the liver, Minutia’s method involves placement just beneath the skin. This significantly simplifies the procedure, reducing surgical risks and expanding accessibility to thousands of clinics worldwide. Ultimately, Minutia's solution could eliminate daily insulin injections, drastically enhancing quality of life for millions of people living with T1D.
Minutia is backed by leading scientists and clinicians from top institutions such as UCSF and Duke and advised by seasoned biotech industry veterans. With $7M secured in non-dilutive funding and strong support from prominent backers like SOSV and IndieBio, Minutia is positioned to redefine diabetes care on a global scale.
Demos Studio
Demos Studio
Demos Studio combines decades of world-class brand strategy and creative expertise with a nimble approach that works at the pace and cost structure that early-stage startups require. We also work with companies we haven’t invested in (yet?)
World Economic Forum & Uplink Top Investor
We’re excited to announce that Demos has been named a Top Investor by the World Economic Forum.
We were selected through the recent Uplink/World Economic Forum challenge to “source and select the most innovative investment, philanthropic and corporate funds that are investing much-needed capital in people and planet-focused entrepreneurs.”
Funds were evaluated based on their investment track record and approach, and our unique model of combining capital with creative and strategic services was specifically called out as an innovative model and one of the reasons Demos was selected.
The video below provides a summary of our model and startup partners to date.
